1. Home
  2. WINT vs CISS Comparison

WINT vs CISS Comparison

Compare WINT & CISS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WINT
  • CISS
  • Stock Information
  • Founded
  • WINT 1992
  • CISS 2022
  • Country
  • WINT United States
  • CISS Greece
  • Employees
  • WINT N/A
  • CISS N/A
  • Industry
  • WINT Biotechnology: Biological Products (No Diagnostic Substances)
  • CISS Marine Transportation
  • Sector
  • WINT Health Care
  • CISS Consumer Discretionary
  • Exchange
  • WINT Nasdaq
  • CISS Nasdaq
  • Market Cap
  • WINT 2.2M
  • CISS 2.5M
  • IPO Year
  • WINT 1995
  • CISS N/A
  • Fundamental
  • Price
  • WINT $0.14
  • CISS $3.03
  • Analyst Decision
  • WINT Hold
  • CISS
  • Analyst Count
  • WINT 1
  • CISS 0
  • Target Price
  • WINT $350.00
  • CISS N/A
  • AVG Volume (30 Days)
  • WINT 5.2M
  • CISS 257.4K
  • Earning Date
  • WINT 08-26-2025
  • CISS 09-02-2025
  • Dividend Yield
  • WINT N/A
  • CISS N/A
  • EPS Growth
  • WINT N/A
  • CISS N/A
  • EPS
  • WINT N/A
  • CISS N/A
  • Revenue
  • WINT N/A
  • CISS $38,174,754.00
  • Revenue This Year
  • WINT N/A
  • CISS N/A
  • Revenue Next Year
  • WINT N/A
  • CISS N/A
  • P/E Ratio
  • WINT N/A
  • CISS N/A
  • Revenue Growth
  • WINT N/A
  • CISS N/A
  • 52 Week Low
  • WINT $0.10
  • CISS $2.85
  • 52 Week High
  • WINT $662.00
  • CISS $22.80
  • Technical
  • Relative Strength Index (RSI)
  • WINT 24.01
  • CISS 38.84
  • Support Level
  • WINT $0.45
  • CISS $2.88
  • Resistance Level
  • WINT $0.51
  • CISS $3.80
  • Average True Range (ATR)
  • WINT 0.08
  • CISS 0.27
  • MACD
  • WINT -0.05
  • CISS -0.01
  • Stochastic Oscillator
  • WINT 8.93
  • CISS 16.30

About WINT Windtree Therapeutics Inc.

Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.

About CISS C3is Inc.

C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.

Share on Social Networks: